The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL406117     N-[4-(3-aminopropylamino) butylcarbamoyl...

Synonyms: AC1L1IXJ, AC1Q5PCX, LS-74244, NSC356894, FT-0631032, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Gusperimus


High impact information on Gusperimus


Chemical compound and disease context of Gusperimus


Biological context of Gusperimus


Anatomical context of Gusperimus


Associations of Gusperimus with other chemical compounds


Gene context of Gusperimus


Analytical, diagnostic and therapeutic context of Gusperimus


  1. Effects of 15-deoxyspergualin on experimental autoimmune giant cell myocarditis of the rat. Kodama, M., Zhang, S., Hanawa, H., Saeki, M., Inomata, T., Suzuki, K., Koyama, S., Shibata, A. Circulation (1995) [Pubmed]
  2. LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level. Ducoroy, P., Micheau, O., Perruche, S., Dubrez-Daloz, L., de Fornel, D., Dutartre, P., Saas, P., Solary, E. Blood (2003) [Pubmed]
  3. Preclinical antitumor activity and pharmacological properties of deoxyspergualin. Plowman, J., Harrison, S.D., Trader, M.W., Griswold, D.P., Chadwick, M., McComish, M.F., Silveira, D.M., Zaharko, D. Cancer Res. (1987) [Pubmed]
  4. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. Tepper, M.A., Nadler, S.G., Esselstyn, J.M., Sterbenz, K.G. J. Immunol. (1995) [Pubmed]
  5. 15-Deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis. Kawada, M., Masuda, T., Ishizuka, M., Takeuchi, T. J. Biol. Chem. (2002) [Pubmed]
  6. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Nadler, S.G., Tepper, M.A., Schacter, B., Mazzucco, C.E. Science (1992) [Pubmed]
  7. The immunosuppressant 15-deoxyspergualin [correction of 1,5-deoxyspergualin] reveals commonality between preT and preB cell differentiation. Wang, B., Benoist, C., Mathis, D. J. Exp. Med. (1996) [Pubmed]
  8. Heterologous immunity provides a potent barrier to transplantation tolerance. Adams, A.B., Williams, M.A., Jones, T.R., Shirasugi, N., Durham, M.M., Kaech, S.M., Wherry, E.J., Onami, T., Lanier, J.G., Kokko, K.E., Pearson, T.C., Ahmed, R., Larsen, C.P. J. Clin. Invest. (2003) [Pubmed]
  9. Cyclosporine, FK-506 and other drugs in organ transplantation. Morris, P.J. Curr. Opin. Immunol. (1991) [Pubmed]
  10. Deoxyspergualin for liver graft rejection. Groth, C.G., Ohlman, S., Ericzon, B.G., Barkholt, L., Reinholt, F.P. Lancet (1990) [Pubmed]
  11. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo. Harrison, S.D., Brockman, R.W., Trader, M.W., Laster, W.R., Griswold, D.P. Investigational new drugs. (1987) [Pubmed]
  12. Effects of cyclosporine and 15-deoxyspergualin on coronary arteriosclerosis after heart transplantation in the rat. Nagamine, S., Ohmi, M., Tabayashi, K., Iguchi, A., Mohri, H. J. Heart Lung Transplant. (1994) [Pubmed]
  13. 15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease after allogeneic bone marrow transplantation. Kasai, M., Higa, T., Naohara, T., Masauzi, N., Watanabe, M., Matsuura, A., Ohizumi, H., Tanaka, J., Morii, K., Kiyama, Y. Bone Marrow Transplant. (1994) [Pubmed]
  14. High-dose 15-deoxyspergualin monotherapy surpasses methylprednisolone in its therapeutic effect on advanced lupus nephritis in New Zealand black/white F1 hybrid mice, and low-dose combination may be synergistic. Okubo, M., Inoue, K., Amemiya, K., Kobayashi, N., Masaki, Y., Kamata, K. Nephrol. Dial. Transplant. (1993) [Pubmed]
  15. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. Hirao, A., Kawano, Y., Takaue, Y. Blood (1993) [Pubmed]
  16. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Dhingra, K., Fritsche, H., Murray, J.L., LoBuglio, A.F., Khazaeli, M.B., Kelley, S., Tepper, M.A., Grasela, D., Buzdar, A., Valero, V. Cancer Res. (1995) [Pubmed]
  17. Clinical pharmacology of deoxyspergualin in patients with advanced cancer. Muindi, J.F., Lee, S.J., Baltzer, L., Jakubowski, A., Scher, H.I., Sprancmanis, L.A., Riley, C.M., Vander Velde, D., Young, C.W. Cancer Res. (1991) [Pubmed]
  18. The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation. Holcombe, H., Mellman, I., Janeway, C.A., Bottomly, K., Dittel, B.N. J. Immunol. (2002) [Pubmed]
  19. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. Hoeger, P.H., Tepper, M.A., Faith, A., Higgins, J.A., Lamb, J.R., Geha, R.S. J. Immunol. (1994) [Pubmed]
  20. The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. Panjwani, N., Akbari, O., Garcia, S., Brazil, M., Stockinger, B. J. Immunol. (1999) [Pubmed]
  21. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Thomas, J.M., Contreras, J.L., Smyth, C.A., Lobashevsky, A., Jenkins, S., Hubbard, W.J., Eckhoff, D.E., Stavrou, S., Neville, D.M., Thomas, F.T. Diabetes (2001) [Pubmed]
  22. Prolongation of graft survival in allogeneic islet transplantation by (-) 15-deoxyspergualin in the rat. Walter, P.K., Dickneite, G., Schorlemmer, H.U., Sedlacek, H.H., Jäger, S., Feifel, G., Seitz, G. Diabetologia (1987) [Pubmed]
  23. Deoxyspergualin inhibits mesangial cell proliferation and major histocompatibility complex class II expression. Nikolic-Paterson, D.J., Tesch, G.H., Lan, H.Y., Foti, R., Atkins, R.C. J. Am. Soc. Nephrol. (1995) [Pubmed]
  24. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. Min, W.P., Zhou, D., Ichim, T.E., Strejan, G.H., Xia, X., Yang, J., Huang, X., Garcia, B., White, D., Dutartre, P., Jevnikar, A.M., Zhong, R. J. Immunol. (2003) [Pubmed]
  25. Importance of the Gal alpha1-3 Gal antigen in discordant islet xenotransplantation: immunosuppression, which inhibits porcine islet xenograft rejection in ordinary mice, is equally effective in Gal-knockout mice. Wennberg, L., Song, Z., Bennet, W., Sandberg, J.O., Sundberg, B., Thall, A., Korsgren, O. Transplantation (2004) [Pubmed]
  26. Clinically significant drug interactions with new immunosuppressive agents. Mignat, C. Drug safety : an international journal of medical toxicology and drug experience. (1997) [Pubmed]
  27. Contribution of heat shock proteins to cell protection from complement-mediated lysis. Fishelson, Z., Hochman, I., Greene, L.E., Eisenberg, E. Int. Immunol. (2001) [Pubmed]
  28. Prevention of type I diabetes in the non-obese diabetic (NOD) mouse with 15-deoxyspergualin (15-DS) or 15-DS + cyclosporin A (CyA). Haberstroh, J., Wilhelm, T., Schulte-Mönting, J., Schorlemmer, H.U., von Specht, B.U. Immunol. Lett. (1995) [Pubmed]
  29. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Farinha, C.M., Nogueira, P., Mendes, F., Penque, D., Amaral, M.D. Biochem. J. (2002) [Pubmed]
  30. Effects of 15-deoxyspergualin in vitro and in vivo on cytokine gene expression. Zhu, X., Imamura, M., Tanaka, J., Han, C.W., Hashino, S., Imai, K., Asano, M., Nakane, A., Minagawa, T., Kobayashi, M. Transplantation (1994) [Pubmed]
  31. In vivo effects of the immunosuppressant 15-deoxyspergualin on hematopoiesis in murine allogeneic bone marrow chimeras. Its thrombopoietic activity and reversal of adverse effects with granulocyte colony-stimulating factor and/or erythropoietin. Imamura, M., Han, M., Hashino, S., Kobayashi, H., Imai, K., Kobayashi, S., Tanaka, J., Zhu, X., Kobayashi, M., Fujii, Y. Transplantation (1994) [Pubmed]
  32. The activity of deoxyspergualin in multidrug-resistant cells. Holmes, J.A., Twentyman, P.R. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  33. Inhibition of nitric oxide synthase induction by 15-deoxyspergualin in a cultured macrophage cell line, J774A.1 [correction of J744A.1] activated with IFN-gamma and LPS. Nosaka, C., Kunimoto, S., Atsumi, S., Takeuchi, T. J. Antibiot. (1999) [Pubmed]
  34. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Gores, P.F., Najarian, J.S., Stephanian, E., Lloveras, J.J., Kelley, S.L., Sutherland, D.E. Lancet (1993) [Pubmed]
  35. Transplantation of porcine fetal pancreas to diabetic patients. Groth, C.G., Korsgren, O., Tibell, A., Tollemar, J., Möller, E., Bolinder, J., Ostman, J., Reinholt, F.P., Hellerström, C., Andersson, A. Lancet (1994) [Pubmed]
  36. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. Asiedu, C.K., Goodwin, K.J., Balgansuren, G., Jenkins, S.M., Le Bas-Bernardet, S., Jargal, U., Neville, D.M., Thomas, J.M. J. Immunol. (2005) [Pubmed]
WikiGenes - Universities